Necrotizing pneumonia due to femoral osteomyelitis caused by community-acquired methicillin-resistant Staphylococcus aureus

Internal Medicine

Volumn 52, Issue 13, 2013, Pages 1531-1536

  Iwanaga, Naoki ^a,b   Fukuda, Yuichi ^a   Nakamura, Shigeki ^b   Imamura, Yoshifumi ^b   Miyazaki, Taiga ^b   Izumikawa, Koichi ^b   Kakeya, Hiroshi ^b   Yanagihara, Katsunori ^b   Soda, Hiroshi ^a   Tashiro, Takayoshi ^b   Kohno, Shigeru ^b  

^a Sasebo Shiritsu Sogo Hospital   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Community acquired methicillin resistant staphylococcus aureus; Necrotizing pneumonia; Osteomyelitis

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; COTRIMOXAZOLE; EXOTOXIN; FIBRINOGEN DEGRADATION PRODUCT; GABEXATE MESILATE; HEPARIN; LEVOFLOXACIN; MINOCYCLINE; PROCALCITONIN; UROKINASE; VANCOMYCIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOMEGALY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYTIC THERAPY; HEART AUSCULTATION; HUMAN; INFLAMMATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OSTEOMYELITIS; PNEUMONIA; POLYMERASE CHAIN REACTION; SPUTUM CULTURE; THORAX RADIOGRAPHY;

ADULT; COMMUNITY-ACQUIRED INFECTIONS; FEMUR; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; PNEUMONIA, STAPHYLOCOCCAL;

EID: 84879659996     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.9561     Document Type: Article

References (35)

1. Barrett FF, McGehee RF Jr, Finland M. Methicillin-resistant Staphylococcus aureus at Boston City Hospital: bacteriologic and epidemiologic observations. N Engl J Med 279: 441-448, 1968.
2. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 32 (Suppl 2): S114-S132, 2001.
3. Centers for Disease Control. Community-acquired methicillinresistant Staphylococcus aureus infections-Michigan. MMWR Morb Mortal Wkyl Rep 30: 185-187, 1981.
4. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46: S368-S377, 2008.
5. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis 54: 1126-1133, 2012.
6. Francis JS, Doherty MC, Lopatin U, et al. Severe communityonset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40: 100-107, 2005.
7. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44: S27-S72, 2007.
8. Wiersma P, D'Angelo T, Daley R, et al. Surveillance for severe community-associated MRSA infection. Epidemiol Infect 137: 1674-1678, 2009.
9. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for PVL and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 359: 753-759, 2002.
10. Tomita Y, Kawano O, lchiyasu H, et al. Two cases of severe necrotizing pneumonia caused by community-acquired methicillinresistant Staphylococcus aureus. The Journal of the Japanese Respriratory Society 46: 395-403, 2008.
11. Gando S, Iba T, Eguchi Y, et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation(JAAM DIC) Study Group: A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 34: 625-631, 2006.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In: Fifteenth informational supplement. M-100-S15. Clinical and Laboratory Standards Institute, Wayne, PA, 2003.
13. Germel C, Haag A, Söderquist B. In vitro activity of beta-lactam antibiotics to community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 31: 475-480, 2012.
14. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 5: 275-286, 2005.
15. Wong KS, Lin TY, Huang YC, Hsia SH, Yang PH, Chu SM. Clinical and radiographic spectrum of septic pulmonary embolism. Arch Dis Child 87: 312-315, 2002.
16. Lin MY, Rezai K, Schwartz DN. Septic pulmonary emboli and bacteremia associated with deep tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. J Clin Microbiol 46: 1553-1555, 2008.
17. Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 41: 583-590, 2005.
18. Minnesota Department of Health. Community-associated methicillin-resistant Staphylococcus aureus in Minnesota. In: Disease Control Newsletter. Minnesota Department of Health, 2004: 61-72.
19. David M, Daum R. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Micro Rev 23: 616-687, 2010.
20. Motoshima M, Yanagihara K, Morinaga Y, et al. Genetic diagnosis of community-acquired MRSA: a multiplex real-time PCR method for Staphylococcal cassette chromosome mec typing and detecting toxin genes. Tohoku J. Exp. Med 220: 165-170, 2010.
21. Moriyama H, Matsuda C, Shibata H, Nishimura N, Hirose M, Nagai A. Usefulness of phage ORF typing, a rapid genotyping method as a molecular and epidemiological method for detecting methicillin resistant Staphylococcus aureus. Kansenshogaku Zasshi 86: 115-120, 2012 (in Japanese, Abstract in English).
22. Nada T, Yagi T, Ohkura T, et al. Usefulness of phage open-reading frame typing method in an epidemiological study of an outbreak of methicillin-resistant Staphylococcus aureus infections. Jpn J Infect Dis 62: 386-389, 2009.
23. Yanagihara K, Araki N, Watanabe S, et al. Antimicrobial susceptibility and molecular characteristics of 857 methicillin-resistant Staphylococcus aureus isolates from 16 medical centers in Japan (2008-2009): nationwide survey of community-acquired and nosocomial MRSA. Diagn Microbiol Infect Dis 72: 253-257, 2012.
24. Konig B, Prevost G, Piemon Y, et al. Effects of Staphylococcus aureus leukocidins on inflammatory mediator release from human granulocytes. J Infect Dis 171: 607-613, 1995.
25. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 45: 315-321, 2007.
26. Campo MR, Hachem Y, Jiang T, et al. Panton valentine Leukocidin exotoxin has no effect on the outcome of cancer patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Medicine (Baltimore) 90: 312-318, 2011.
27. Lalani T, Federspiel JJ, Boucher HW, et al. Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. J Clin Microbiol 46: 2890-2896, 2008.
28. Tseng CW, Kyme P, Low J, et al. Staphylococcus aureus Panton-Valentine leukocidin contributes to inflammation and muscle tissue injury. PLoS ONE 4: e6387, 2009.
29. Labandeira RM, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 315: 1130-1133, 2007.
30. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290: 2976-2984, 2003.
31. Guidelines for the Management of Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections in the US Navy and Marine Corps. Navy Environmental Health Center, August 2006.
32. Barton-Forbes M, Hawkes M, Moore D, et al. Guidelines for the prevention and management of community associated methicillin resistant Staphylococcus aureus (CA-MRSA): a perspective for Canadian health care practitioners. Can. J Infect Dis Med Microbiol 17(Suppl. C): 1B-24B, 2006.
33. Scott TM, Michael D, Marin HK. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: Importance of treatment with antimicrobials inhibiting exotoxin production. Chest 128: 2732-2738, 2005.
34. Wargo K, Eliand E. Appropriate antimicrobial therapy for community-acquired MRSA carrying the PVL genes. Clin Infect Dis 40: 1376-1378, 2005.
35. George KS, Tsigereda T, Karen C, James D. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 37: 1257-1260, 2003.